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ABSTRACT 
 
The ε4 allele of the apolipoprotein E (APOE) gene is a strong risk factor for developing late-
onset Alzheimer’s disease (LOAD), accounting for about half of the genetic component of the 
disease risk. Recent investigations into the mechanisms by which APOE4 contributes to the 
pathology of LOAD is offering new perspectives on how the disease may be treated in the future, 
and even though further research is needed before any such drugs will be made available, we 
may see the emergence of strategies for genotype-specific prevention and therapy. Current 
efforts are focused on how apolipoprotein E isoforms affect different aspects of the disease 
process, including the production and clearance of amyloid-β peptide, amyloid neurotoxicity, 
tangle formation, cholesterol homeostasis, and synaptic plasticity and repair. Since carrier status 
at present offers no benefits in terms of more accurate prognosis or better therapy, genotyping is 
discouraged for all other purposes than research, and there are concerns about the mental health 
of susceptible individuals receiving discouraging results. There are ethnical and geographical 
variations in the distribution of the APOE4 allele and in its association with LOAD. This, along 
with the fact that the APOE4 allele is neither sufficient nor necessary for the development of 
LOAD, prompts us to think that we are only beginning to get a grasp on how to counteract this 
leading cause of dementia, in a world where demographics are presenting us with more care 
demanding elderly than ever before.  
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INTRODUCTION 
 
On the 14
th
 of April 2003, a statement was released by the International Human Genome 
Sequencing Consortium, announcing the successful completion of the Human Genome Project. 
This entailed that about 99 % of the human genome’s gene-containing regions had been 
sequenced to an accuracy of 99.99 % (1). However, inherited genetic variance has a critical role 
in human disease, and the Human Genome Project shed little light on this variance, having been 
completed by sequencing the DNA of just a few anonymous donors (2). The HapMap project 
was subsequently launched in order to map the millions of single nucleotide polymorphisms 
which make each individual unique (3). Despite the ever-accelerating pace of biomedical 
research, and the fast increasing amount of knowledge we have of the human genome, root 
causes of human diseases are still largely unknown. Genetic inheritance seems to play a vital role 
in nearly all of them, and a lot of emphasis is now being placed on making the connections. 
Investigations into how individual genes contribute to pathology may allow earlier diagnosis, 
better preventive measures, and maybe even curative treatments. 
The term polymorphism, originally coined by E B Ford as early as 1940, during his 
investigations into human blood groups, was originally used in biology to describe two or more 
different phenotypes occurring at the same time in the same species (4). The definition most used 
in current genetics is that a polymorphism is a genetic variation that occurs with at least 1 % 
frequency in a population (5). In this paper, I intend to describe one such polymorphism, namely 
that of the apolipoprotein E, and investigate its effects on neurological disease in humans. 
 
Apolipoprotein E 
Apolipoproteins were discovered in the early 1960s, as scientists were beginning to dissect 
human lipoproteins, providing the possibility to isolate smaller components. The name itself was 
first suggested by J L Oncley, a professor of bio-chemistry at the University of Michigan (6). 
The prefix apo, meaning separate or detached, suggests that an apolipoprotein is the protein 
moiety in its lipid-free form (7).  
Apolipoprotein E (apoE), initially termed the arginine-rich apoprotein, was first identified as a 
constituent of very-low-density lipoprotein (VLDL) in 1973, by Shore and Shore (8). It was 
subsequently demonstrated that apoE is present not only in VLDL, but in chylomicrons, low-
density lipoprotein (LDL) and high-density lipoprotein (HDL). The function of apoE became 
clear shortly after its discovery, and by 1982 numerous experiments had shown that it was 
important in the catabolism of lipoproteins, both in hepatic and extrahepatic tissues (9). The first 
clue to the possible detrimental effects of one of its polymorphisms was also presented as early 
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as in 1973, when a strong association was shown between apoE and type III 
hyperlipoproteinemia (10).  
The polymorphic nature of the apolipoprotein, however, was not clearly established until the 
early 1980s (11;12). The nomenclature designating the three major isoproteins as apoE2, apoE3, 
and apoE4, was set in 1982, along with the classification of the alleles that produced them 
(APOE2, APOE3, APOE4), and the certification of the fact that they belong to a single gene 
locus, on chromosome 19 (13;14). Simple genetics then dictated that six different phenotypes 
existed, three homozygous (apoE2/2, E3/3, and E4/4) and three heterozygous (apoE2/3, E2/4, 
and E3/4) (14). Subsequent population studies revealed that the most common phenotype is 
apoE3/3 and that the most common allele is APOE3, leaving apoE3 to be considered the parent 
protein, while E2 and E4 were considered the variants (15;16). Apolipoprotein E2 came to be 
most commonly associated with type III hyperlipoproteinemia, and was found to be defective in 
receptor binding (17), while apoE4 displayed normal receptor binding, but was associated with 
elevated plasma cholesterol and LDL, thus predisposing carriers to coronary artery disease (18).  
By 1988, it had been discovered that apoE had more functions than previously assumed. A major 
function was indeed that of transporting lipids from sites of synthesis or absorption to sites of 
utilization, but equally important was deemed its role of redistributing lipid within a tissue 
during injury and repair. ApoE was found to be synthesized in various cell types, such as 
hepatocytes, macrophages, astrocytes and smooth muscle cells. The large accumulation of apoE 
in response to nerve injury suggested the possibility of involvement in processes like neurite 
membrane biosynthesis and myelin formation. ApoE was also suspected of playing a role in 
smooth muscle cell proliferation and differentiation (8). 
 
An unexpected revelation 
Even though the perceived role of apolipoprotein E had expanded during the late 1980s, focus 
remained on apoE4’s involvement in elevated levels of total and LDL-cholesterol, and the 
elevated risk of coronary artery disease for its carriers (19). Therefore, in 1993, it was considered 
a major breakthrough when Warren J Strittmatter, Allen D Roses, and colleagues, published an 
article that suggested A functional role of the apolipoprotein E-E4 isoform in the pathogenesis of 
late-onset familial Alzheimer disease. They had found that apolipoprotein E was 
immunochemically localized to the senile plaques, vascular amyloid, and neurofibrillary tangles 
of Alzheimer’s disease (AD). Furthermore, their investigation into the frequency of apoE alleles 
in Alzheimer patients and controls showed a highly significant association between apoE4 alleles 
and late-onset familial Alzheimer’s disease (LOAD) (20).  
The following years, a lot of material was published regarding the association between apoE4 
and certain types of neurological disease. In 1995, a much cited review by Strittmatter and 
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Roses, Apolipoprotein E and Alzheimer disease, summarized the early years of this research. In 
it, they stated with little ambiguity that inheritance of specific apoE alleles, in large part 
determines the risk and mean age of onset of late-onset familial and sporadic Alzheimer disease. 
They had evidence of isoform-specific differences in the binding of apoE to the microtubule-
associated tau-protein, which constitutes most of the neurofibrillary tangles (FIG 1A) in AD, and 
to amyloid-β peptide, which is a major component in neuritic plaque (FIG 1B) (21).  A year later, 
another review was published under the same name. The second review was much more 
comprehensive, and provided even more certainty that previous assumptions had been justified. 
Little groundbreaking information was given, however, it was stated more clearly than before 
that the APOE4 allele indeed increased the probability of disease at an earlier age, and that the 
APOE2 and APOE3 alleles decreased the probability of disease and increased the age of onset 
(22).  
 
 
 
 
 
Association with other diseases in the 20th century 
Already in their breakthrough article of 1993, Strittmatter and Roses had noted that apoE 
synthesis increased following injury, and was similarly increased in several chronic 
neurodegenerative disorders, not just in Alzheimer’s disease (20). In 1991, scientists had found 
high levels of apoE in the amyloid plaques of Creutzfeldt-Jakob disease (22). Over the following 
decade, apoE4 was linked to earlier onset and more severe progression of diabetic neuropathy 
(23), while studies concerning human immunodeficiency virus (HIV)-related neuropathy, motor 
neuron disease and amyotrophic lateral sclerosis (ALS), were too methodically weak to provide 
A B 
Figure 1 | Gallyas staining, 40x objective. A – Neurofibrillary tangles. B – Neuritic plaque. Oslo University 
Hospital Ulleval. 
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any solid leads (24). In Guam, two studies regarding the ALS/parkinsonism/dementia complex, 
found significantly lower frequencies of apoE2 in patients compared to controls, suggesting a 
protective function of apoE2 (25;26). Concerning cerebral amyloid angiopathy, apoE4 was 
shown to be a risk factor, with or without pathological evidence of AD (27;28) Two individual 
studies demonstrated elevated APOE4 frequencies among patients with Lewy body dementia 
(29;30), and among the AD-prone patients with Down syndrome, several studies had shown an 
earlier age of dementia onset for APOE4 carriers, and significant protection against dementia 
from APOE2 (31).  
ApoE4 was perceived to influence all neurodegenerative disorders associated with the deposition 
of amyloid-β peptide (Aβ), while apoE variation was not shown to have any effect on the 
prevalence of disorders such as Parkinson’s disease without dementia, progressive supranuclear 
palsy, ALS, multiple sclerosis (MS), Huntington’s disease, depression or schizophrenia (32). 
There was no consistent association between apoE4 and Creutzfeldt-Jakob disease (33) or HIV-
associated dementia (34). Thus, apoE4 remained firmly linked only to neurological disorders 
involving the deposition of Aβ (32). 
A review from 2000 found a moderately increased risk of coronary artery disease among apoE4 
carriers (32), and a 1999 meta-analysis concerning ischemic cerebrovascular disease found a 
moderately increased risk for patients with apoE4 as well (35). Further elucidating its role in 
cholesterol metabolism, apoE4 was shown to increase the cholesterol content of gallstones, and 
also to increase the prevalence of gallstones in women (36). 
Interestingly, there was shown no connection between the neurological and cardiovascular risk 
induced by apoE4. A large epidemiological study in New York found no consistent relationship 
between apoE genotype, plasma cholesterol and AD among its elderly (37), and a large case-
control study in Rotterdam concluded that apoE4’s effect on dementia was not through 
atherosclerosis (38). 
Regarding diseases neither neurological nor cardiovascular, one longitudinal study involving 
1750 women over the age of 65, showed an increased rate of bone loss for E4 carriers, and an 
increased frequency of hip fractures, even after correcting for age, mental status and bone 
mineral density (39). ApoE was shown to be implicated in immunoresponses against various 
infectious agents, but no certain relation to phenotype variants had been shown by 2000 (40). 
Finally, from the Strittmatter/Roses breakthrough in 1993, until 2000, the association between 
the APOE4 allele and Alzheimer’s disease was one of the most repeated findings in medical 
genetics (32). 
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Geographical distribution 
The APOE gene is structurally similar to some of the APOA and APOC genes, and is thought to 
have diverged from the APOA-I and APOA-IV genes some 420 million years ago (41). Research 
to date indicates that APOE4 is the ancestral allele of E2 and E3. Almost all animal APOE more 
closely resembles the human APOE4, including that of all the great apes (42). Furthermore, 
Fullerton et al. identified sequence haplotype
1
 variation for the whole APOE locus among an 
ethnically diverse sample, and inferred from the pattern of haplotype relationships that APOE2 
and E3 are derived from the genetically older APOE4 (43).  
It may seem strange that the now deleterious APOE4 allele was the origin of the apparently more 
beneficial other two. However, the APOE4 may have been rendered causal of diseases like 
coronary artery disease and Alzheimer’s disease, by environmental conditions such as a longer 
lifespan and the western diet. This idea is supported by the fact that APOE4 is not associated 
with either disorder in sub-Saharan Africans, but it is associated with both of them in African 
Americans (44). 
Globally, the APOE locus shows substantial allelic variation. APOE2 ranges from 0-20 %, 
APOE3 ranges from 60-90 %, and APOE4 ranges from 10-20 % (44), with a few exceptions 
(45). The APOE3 allele is the most frequent in all human groups, especially in populations 
where an agricultural economy was established early, such as in the Mediterranean basin, where 
it ranges from 0.849 to 0.898. The frequency of the APOE4 allele remains higher in indigenous 
populations where an economy of foraging still exists, or food supply is scarce and sporadically 
available, e.g. among aborigines, pygmies or Native Americans. Interestingly, the APOE4 allele 
is absent in the tribal population of Koch, India (45). The APOE2 frequency fluctuates with no 
apparent trend, and is absent in Native Americans (44). Figure 2 shows APOE4 distribution 
worldwide, below. 
Possible explanations for the geographical distribution of the alleles exist. APOE4 carriers are 
thought to be more responsive to dietary fats, and to have better absorption of lipids and fat-
soluble vitamins. This presents an advantage when food sources are scarce, and may be the 
reason why it is more common in populations that up until recently have been hunter-gatherers 
(44). Although APOE4 has been found to be causative in many diseases, it still occurs at high 
frequencies in some populations. Pre-historical selective benefits probably outweigh its disease 
cost (45). In long-established agricultural communities, e.g. southern Europe, Southeast Asia and 
Central America, it is possible that APOE3 was selectively favored once populations reached the 
                                                          
1 Alleles located in close proximity on the same chromosome that, as a result, are inherited together. In a population, 
the genome is partitioned into haplotype blocks of varying length depending on the strength of the linkage 
disequilibrium between the alleles, and the different combinations of alleles that are located in these blocks are 
called haplotype clades or haplotype alleles. 
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critical size needed to sustain certain viral infections, from which it provided better protection 
than APOE4  (40), or that the late cognitive impairment produced by APOE4 was a disadvantage 
 
 
 
when family elders needed to pass on more complex information, thus providing worse 
conditions for their young (46). Another factor may be that the APOE allele influences 
reproductive efficiency, one study has shown that male homozygous APOE3 carriers have more 
children than carriers of APOE2 and APOE4 (47).  
In Europe, there is a significant south to north increasing cline of the APOE4 allele, and the 
APOE4 frequency worldwide is generally higher in dark-skinned people(45). This may be 
explained by APOE4’s association with better intestinal absorption of vitamin D, more sorely 
needed where sunlight is scarce or in dark-skinned people, thus influencing natural selection 
(45).  
Finally, factors such as genetic drift, local selection, and isolation by distance cannot be excluded 
when attempting to explain the variance of APOE genotypes around the world. In any case, the 
existing population diversity clearly indicates that the APOE polymorphism is a useful 
anthropogenic marker for population genetic studies (45). 
  
Figure 2 | Worldwide distribution of the APOE4 allele. Figure is from Singh et al. 2006, with corrections made 
according to Kumar et al. 2002 and Raygani et al. 2005. 
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PROBLEM 
 
The different alleles of the apolipoprotein E polymorphism have a large impact on human health. 
In fact, one could claim that since this single gene variation has had a major influence on human 
evolution, and has a central role in the pathogenesis of Alzheimer’s disease, the variation in the 
APOE-gene is one of the most important polymorphisms within the science of genetics. 
Therefore, this paper is written with the intention of providing answers to the following 
questions:  
What impact does the apolipoprotein E4 have on the risk of developing Alzheimer’s disease? 
What are some of the pathological mechanisms by which the apolipoprotein E4 contributes to the 
development of Alzheimer’s disease?  
Does knowledge of these mechanisms reveal any new insight into the possible treatment of 
Alzheimer’s disease? 
Does apolipoprotein E genotyping offer any benefit to patients of Alzheimer’s disease, in terms 
of prognosis, risk reduction or treatment?  
 
ASSESSMENT OF DEMENTIA 
In most patients 
 Imaging of head (CT/MRI) 
 Blood test 
o Full blood count, ESR 
o Urea, electrolytes, glucose 
o Calcium, liver function tests 
o Thyroid function tests 
o Vitamin B12 
o Venereal Disease Reference Lab test 
o ANA, anti-dsDNA 
 Chest radiograph 
 EEG 
In selected patients 
 Lumbar puncture 
 HIV serology 
 Brain biopsy 
  
Table 1 | From Davidson’s Principles and Practice of 
Medicine 2002.  Should APOE genotyping appear 
somewhere in this box? 
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METHODS 
 
This non-systematic review has been completed by 6
th
-year medical student at the University of 
Oslo, Einar Aronsen, under the supervision of Professor Jan Maehlen, M.D., Ph.D. Searches 
were made on the Cochrane libraries, PubMed, and MEDLINE. With the exception of the 
Lehninger Principles of Biochemistry (7) and Davidson’s Principles and Practice of Medicine 
(48), no textbooks were used. Some online resources have been quoted: the official websites of 
The International Human Genome Sequencing Consortium, the AlzGene database, and the Norsk 
Elektronisk Legehandbok (the Norwegian Electronic Doctor’s Handbook). 
Search-words were: Alzheimer, apoE, apoE4, apolipoprotein E, apolipoprotein E4, 
atherosclerosis, cardiovascular disease, distribution, genetic testing, history, polymorphism, and 
combinations of these using AND and NOT. No further limitations were placed on searches. 
Additional searches were made using authors and titles from references listed in articles 
produced by primary searches. 
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ALZHEIMER’S DISEASE 
 
The role of the apolipoprotein E4 polymorphism 
Alzheimer’s disease (AD) in a given patient can be categorized as either early-onset AD, which 
is inherited in a classic autosomal dominant manner
2
, or late-onset AD (LOAD), for which the 
pattern of inheritance is much more complex. Early-onset AD is quite rare and accounts for less 
than 2 % of cases (49). All mutations currently known to cause early-onset AD (i.e. onset before 
the age of 60) are located either in the amyloid precursor protein (APP)-gene, or in the presenilin 
protein genes 1 and 2. Mutations in these genes alter the normal processing of APP to the 
amyloid-β peptide (Aβ), the deposition of which is hallmark to all forms of AD, but especially to 
the early-onset form (5). People inheriting one of these autosomally dominant mutations will 
develop AD unless they die prematurely from other causes (49).  
Apolipoprotein E (apoE indicates the protein and APOE indicates the gene) is a plasma protein 
involved in the transport of cholesterol, which is encoded by a gene on chromosome 19 (50). 
Since it was first associated with AD in 1993 (20), confirmations in numerous ethnic populations 
have established APOE genotype as the most important biological marker for susceptibility for 
AD, accounting for 45 % to 60 % of it’s genetic component (51). This bears more relevance for 
investigations into LOAD, but the disproportionate representation of APOE4 is also present in 
patients with early-onset AD  (52). Interestingly, the APOE4 allele is neither necessary nor 
sufficient to cause AD, as at least a third of patients are not carriers of the APOE4 allele and 
almost 50 % of homozygous carriers that survive until the age of 80 do not develop AD (49). 
A meta-analysis by Farrer et al., published in 1997, was the first to present a comprehensive 
overview of the distribution of APOE genotypes around the world, and its effects on AD (49). 
The most recent compilation of these data published on paper came in 2006 (45), and there is a 
publicly available database, called AlzGene, that attempts to keep up with the ever-more rapid 
flow of new investigations (5;53). It is interesting to note that new findings are almost 
completely in harmony with the meta-analysis from 1997, providing only minor adjustments 
based on more in-depth investigations into population minorities and some changes in 
methodology (5;54).  
Heterozygous carriers of the APOE4 allele have an odds ratio
3
 (OR) range of 2.2-4.4 for 
developing AD, using as reference (OR=1) homozygous carriers of the APOE3 allele. The OR 
                                                          
2 A type of inheritance in which the phenotype of a trait is determined completely by one of two alleles on the non-
sexchromosomes. There can be either one (heterozygous state) or two (homozygous state) copies of the dominant 
allele. 
 
3 A measure of effect size (for example, of risk effects). The OR measures the ratio of the odds of an event occurring 
in one group (for example, disease cases) to the odds of that same event occurring in another group (for example, 
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range of homozygous APOE4 carriers is 5.1-34.3. Conversely, the APOE2 allele offers some 
protection from the disease, being underrepresented in AD patients, although the collective 
evidence for this assumption is less comprehensive (49). The APOE genotype is also linked to 
age of onset, in such a fashion that carriers of the APOE4 allele tend to be younger when 
clinically diagnosed, compared to carriers of APOE2 and E3. Also, homozygous carriers of E4 
have an earlier age of onset than heterozygous carriers (55). It is not clear whether APOE 
genotype has any effect on the rate of cognitive decline in AD (56). Although more than 500 
other genes have been assessed as potential LOAD risk factors, none have been consistently 
proven to influence disease risk (5), and none show odds ratio effects even close to those of 
APOE4 (typically less than 1.5 compared to non-carriers) (57). 
According to the AlzGene database, i.e. the most comprehensive and current meta-analysis of 
APOE genotype distribution, the APOE4 allele is present in 38 % of all Caucasian AD patients, 
whereas the number is 14 % for controls. Furthermore, 14.5 % of all Caucasian AD patients are 
homozygous for APOE4, and only 2 % of controls. These numbers come out roughly the same 
when making estimations concerning all races in total, but that is largely due to the fact that a 
large majority of studies completed, have been done with Caucasian subjects (58). In some 
populations, e.g. African Americans and Hispanics, the association between APOE4 and AD 
appears much more uncertain than among Caucasians. It remains unclear whether this is due to 
smaller samples and weaker methodology, or if it is related to differences in genetic and 
environmental background (59). The APOE4-AD association has been described as the strongest 
in studies completed with Japanese subjects (49). 
 
Pathogenesis 
 
Physiological function 
The human apolipoprotein E is a 299 amino acid glycoprotein (60). It is expressed in several 
organs, with the highest expression in the liver, followed by the brain.  Astrocytes, and to some 
extent microglia, express the majority of apoE in the brain (61). Neurons may also exhibit some 
apoE expression, but only under certain conditions (e.g. injury), and at much lover levels than 
astrocytes and microglia (62). ApoE functions as a ligand in receptor-mediated endocytosis of 
lipoprotein particles. In plasma, apoE proteins are present on lipoproteins in association with 
other apolipoproteins, whereas in the brain apoE and two other apolipoproteins, apoJ and apoA-
1, are predominantly present on distinct high-density-like lipoprotein particles (63). The 
predominant apolipoprotein of high-density lipoprotein (HDL) in the central nervous system 
                                                                                                                                                                                           
healthy controls). An OR of 2 indicates that carriers of a certain risk factor are at twice the risk of developing the 
disease as non-carriers; an OR of 0.5 indicates that the risk in carriers is only half that in non-carriers. 
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(CNS) is apoE (64). After receptor-mediated endocytosis of apoE-containing HDL-like particles 
by members of the low-density lipoprotein (LDL) receptor family, apoE may be either degraded 
or recycled back to the cell surface (65). Cholesterol released from apoE-containing lipoprotein 
particles is used to support synaptogenesis and synaptic maintenance (66). Whether this use of 
cholesterol occurs in the uninjured brain remains uncertain, as the brain of APOE knockout mice 
generally appears normal in the absence of injury (66).  
The three isoforms apoE2, apoE3 and apoE4, differ at positions 112 and 158 (8). These single 
amino acid differences among the three apoE isoforms alter the protein’s structure and influence 
its lipid association and receptor binding (67). ApoE4 has the amino acid arginine (Arg) at 
position 112, which affects the conformation of the side chain of Arg61, resulting in domain 
interaction between this Arg61 in the N-terminal domain and Glu255
4
 in the C-terminal domain 
(57). This domain interaction is perceived to be central in causing most of apoE4’s adverse 
effects (FIG 3) (67;68).  
 
 
 
 
 
 
 
  
                                                          
4
 Glutamic acid. 
Figure 3 | Schematic representation of human APOE. The 299 amino acid human apolipoprotein E (APOE) 
contains two independently folded domains: an amino-terminal domain that includes the receptor-binding 
region and a carboxy-terminal domain that contains the major lipid-binding region. The residues that distinguish 
the APOE isoforms (112 and 158) are marked. APOE2 has Cys at both positions, APOE4 has Arg at both positions, 
and APOE3 has Cys at position 112 and Arg at position 158. The domain interaction between Arg61 and Glu255 in 
APOE4 is also indicated (Bu 2009). 
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Aβ production and clearance 
The accumulation, oligomerization and subsequent deposition of amyloid-β in the brain are 
central events in the pathogenesis of AD (57), leading to the presence of amyloid plaque, which 
was immunoreactively shown to contain apoE as early as 1991 (69). Aβ level in the brain is the 
net balance of Aβ production and clearance, and accumulation could consequentially reflect 
overproduction, insufficient clearance, or both (57).  
Several apoE receptors interact with the amyloid precursor protein (APP) and modulate its 
trafficking and processing to Aβ (70). ApoE isoforms differentially regulate APP processing to 
Aβ through these receptors, and apoE4 has been shown to increase Aβ production compared to 
apoE3 (71).  
Aβ is actively cleared from the cerebrospinal fluid, at a rate of 8.3 % per hour (72). This happens 
through two major pathways. One is receptor-mediated clearance by cells in brain parenchyma, 
along the interstitial fluid drainage pathway or through the blood-brain barrier (BBB). The other 
is endopeptidase-mediated proteolytic degradation (57). ApoE receptors are likely to be involved 
in the former, as apoE is a well-characterized chaperone for Aβ (73). Since apoE3 binds to Aβ 
peptides with higher affinity than apoE4 (74), receptor-mediated clearance of Aβ is probably less 
effective for the apoE4 phenotype (75). Furthermore, Aβ binding to apoE4 redirects its clearance 
from the LRP1-receptor
5
 to the VLDL-receptor, which has a slower clearance rate (76). In 
contrast, Aβ binding to apoE2 and E3 induces clearance at both receptor types (57). Even though 
receptor-mediated clearance in principle is an effective way of reducing Aβ levels in the brain, it 
is possible that clearance of Aβ into neurons can lead to intraneuronal Aβ accumulation, which is 
toxic (77).  
As stated above, Aβ can also be removed from the brain by proteolytic degradation. ApoE 
promotes this degradation by way of the enzymes neprilysin and insulin-degrading enzyme, with 
apoE3 being more efficient than apoE4 (78).  
Both post-mortem studies (79) and positron emission tomography imaging studies (80) have 
demonstrated an increased amyloid plaque load in brains of APOE4 carriers. Figure 4 shows the 
influence of the APOE isoforms on the major Aβ clearance pathways in the brain. 
 
 
                                                          
5
 Low-density lipoprotein receptor related protein 1. 
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Neurotoxicity 
Aβ oligomers are highly toxic to neurons, inhibiting the viability of neurons in vitro (81), and the 
memory of animal models (82). ApoE4 augments Aβ oligomer toxicity to a larger extent than 
apoE3 in cultures (81). It has also been found to act synergistically with Aβ aggregates to induce 
neurodegeneration in the mouse brain. Neurodegeneration was not observed in mice that had Aβ 
accumulation due to overproduction induced by mutant APP, only in mice expressing human 
apoE4 (83).  
 
Tangle formation 
Hyperphosphorylated microtubule-associated protein tau (tau) is toxic to neurons, and is the 
main component of neurofibrillary tangles (57). It is essential for Aβ-induced neuronal 
dysfunction, as reducing endogenous tau blocks Aβ-induced cognitive impairments in mouse 
models (84). ApoE4 is normally expressed in neurons only under certain conditions, such as after 
an injury (85). However, an increased tau phosphorylation in neurons has been observed in 
uninjured mice expressing human apoE4, suggesting a neuron-specific effect of apoE4 on tau 
Figure 4 | Major Aβ clearance pathways in the brain: role of APOE isoforms. Amyloid-β (Aβ) accumulation in the 
brain parenchyma leads to the formation of Aβ oligomers and amyloid plaques, which are toxic to neurons.  
Major Aβ clearance pathways include receptor-mediated clearance by cells in the brain parenchyma (neurons 
and glia), along the interstitial fluid drainage pathway and through the blood-brain barrier, and proteolytic 
degradation by endopeptidases. The comparative effects of APOE3 and APOE4 are indicated (Bu 2009). 
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phosphorylation (86). It is possible that in AD brains, abnormal apoE expression in neurons 
facilitates tau hyperphosphorylation (57).  
 
Cholesterol transport 
The primary function of apoE in the brain is to transport cholesterol, mainly from astrocytes to 
neurons. Cholesterol is an essential component of membranes and myelin sheaths and is crucial 
for synaptic integrity and neuronal function (87).  In the adult brain, there is reduced synthesis of 
and increased demand for cholesterol in neurons, which makes the need for active cholesterol 
transport greater. Cholesterol from apoE-lipoprotein particles secreted by astrocytes is essential 
for the formation of synapses in vitro (FIG 5) (88). Cholesterol levels in AD brains are lower 
than in healthy brains (89). There is some evidence that apoE4 may be less efficient than apoE3 
in transporting brain cholesterol (90), and apoE4 is less efficient than apoE3 in promoting 
cholesterol efflux from both neurons and astrocytes (91). Using cultured astrocytes from APOE 
targeted replacement (TR) mice
6
, it was shown that fewer apoE3 than apoeE4 molecules are 
needed to generate lipid particles of a given size, suggesting that apoE3-expressing astrocytes 
can supply neurons with more cholesterol than apoE4-expressing astrocytes (92).  
ApoE also mediates the transport of other brain lipids, such as sulfatide, an oligodendrocyte-
synthesized lipid that is crucial for dendritic spine and myelin sheath integrity. Sulfatide is a 
potential biomarker for AD diagnosis, as its levels are reduced in AD brains (93).  
 
                                                          
6
 A model of human APOE expression in which the human APOE gene is inserted into the mouse APOE gene locus. 
The expression of human APOE in these mice temporally and spatially resembles that of endogenous mouse APOE. 
Figure 5 | Synapse formation 
and repair depend on choles-
terol transport from astrocytes 
to neurons. APOE that is se-
creted by astrocytes assembles 
cholesterol and other lipids into 
lipoprotein particles. Cholesterol 
and other lipids transported to 
neurons have important roles in 
synapse formation and repair. 
The inset shows the main 
components of APOE-
lipoprotein particles: chole-
sterol, cholesterol esters and 
phospholipids (Bu 2009). 
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Synaptic plasticity and dendritic spine integrity 
Synaptic failure is an early pathological feature of AD (94). ApoE-mediated lipid redistribution 
and signaling play important parts in synaptic integrity and plasticity. Increasing evidence 
suggests that apoE isoforms differentially regulate synaptic plasticity and repair. Human APOE4 
TR mice display synaptic deficits in the absence of neuropathology (95). Long-term potentiation, 
i.e. long lasting enhancement of signal transmission between neurons, in the hippocampus of 
APOE4 TR mice is also significantly impaired, compared to APOE3 TR mice and wild-type 
mice (96).  
ApoE expression in the brain is upregulated after neuronal injury. The primary function of 
injury-induced apoE expression is probably to redistribute lipids  and strengthen apoE-mediated 
signaling for neuronal and synaptic repair (57). It has been shown in vitro that apoE3 increases 
neurite outgrowth, whereas apoE4 either decreases outgrowth or has no effect (97). Similarly, 
apoe3-containing lipoprotein particles are more effective than apoE4 particles in protecting CNS 
neurons from apoptosis (98). Collectively, these studies indicate that apoE4 is less effective than 
apoE3 in maintaining and repairing synapses and neurons, which may explain why under certain 
conditions such as severe head trauma and stroke, individuals with apoE4 tend to have a poorer 
outcome. It is possible that LOAD is a result of cumulative injury from Aβ and other neuronal 
stresses, such as oxidation and inflammation, and that APOE4 carriers for this reason are more 
prone to developing LOAD (57).  
The apoE isoforms also differentially regulate dendritic spines during aging. ApoE3-expressing 
and wild-type mice have a higher density of dendritic spines than apoE4-expressing mice at 2 
years of age, but not at 3 weeks of age. This age-dependent difference suggests that the effects of 
the apoE isoforms on neuronal integrity may relate to the increased risk of dementia in aged 
individuals that express apoE4. In patients with AD and in aged controls the apoE4 dose 
inversely correlates with dendritic spine density (99).  
 
Figure 6 | Roles of APOE isoforms in the healthy 
brain and AD pathogenesis. Summary of APOE 
functions in normal brain function and the 
pathogenic processes of AD. Differential regulation 
by APOE3 and APOE4 are indicated. Aβ, amyloid-β; 
LDLR, low-density lipoprotein receptor; LRP1, LDLR-
related protein 1 (Bu 2009). 
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Genetic testing 
 
In prognosis 
While the effect of the APOE4 allele on the risk and age of onset for AD is generally consistent 
in most studies, there have been numerous conflicting reports regarding whether the different 
APOE alleles influence the rate of cognitive decline following dementia onset (56). Craft et al. 
suggested that homozygous carriers of the APOE4 allele suffered a more rapid cognitive decline 
and loss of daily function (100), whereas Frisoni et al. found no such association (101). Growdon 
et al. found that the APOE genotype did not influence the rate of cognitive decline (102), and 
Kurz et al. stated that carriers and non-carriers of the APOE4 allele did not significantly differ in 
cognitive functioning and everyday performance over the first three years after being diagnosed 
with AD (103). Hoyt et al. found that homozygous carriers of the APOE4 allele suffered a slower 
rate of cognitive decline (104). Collectively, these studies may indicate that the mechanisms 
which put APOE4 carriers at greater risk for developing AD either precede or play out their 
influence at an early point in the disease process, or that the biological processes contributing to 
the onset of AD are different from those determining its clinical course. A study by Cosentino et 
al. from 2008 concluded that the APOE4 allele may influence the rate of cognitive decline most 
significantly in the earliest stages of Alzheimer disease (105), more or less in keeping with the 
above hypothesis. Understanding whether APOE plays a mechanistic role in the progression of 
AD is an important question to address in the future (56). 
 
In the eyes of the patient 
Susceptibility testing for AD, i.e. testing for the APOE4 allele, differs in important ways from 
predictive testing for disease-causing polymorphisms, such the presenilin-1 and -2 mutations. It 
is relevant to a much larger at risk population, yet provides much less certain information than 
predictive testing (106). This limitation, coupled with a general lack of treatment options for AD, 
has prompted several consensus statements cautioning against susceptibility testing in 
asymptomatic individuals (107). However, given treatment advances, potential patient demand, 
and clinical trials seeking at-risk samples, there is a need to examine genetic risk assessment for 
AD in a research context (108).  
The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study was published in 
2005, and assessed the following questions regarding genetic susceptibility testing: Who seeks 
genetic assessment and why? How do apolipoprotein E results affect risk perception? What 
psychological impact does genetic risk assessment have? And, how does risk information affect 
participants’ health and insurance behavior? REVEAL was a randomized controlled study, 
among 162 first-degree relatives of AD patients (109). 
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All participants were asked to rate the importance of possible reasons for seeking risk 
assessment. Most important reasons were, in order of importance: to arrange personal affairs; the 
hope that effective treatment will be developed; to arrange long-term care; to prepare relatives 
for the possibility of the disease; to do things sooner than planned; and hope of relief when 
learning of low personal risk. By gauging interest in risk assessment, the REVEAL study found 
that women, college educated people, and persons under the age of 60 are particularly interested 
in having their risk assessed (109). 
Analyses regarding the comprehension and retention of risk information suggested that 
participants recalled their APOE genotype better than their lifetime risk estimate given as a 
percentage. In fact, in a subgroup of women who were all given a lifetime risk estimate of 29 %, 
those learning they had no APOE4 allele had a greater reduction in anxiety than those given no 
APOE information. For patients learning that they did have the APOE4 allele, feelings of anxiety 
were not increased, possibly because they already perceived themselves as being at high risk. 
These findings highlight the powerful effects that genotype information can have on participants, 
even when presented as part of a multivariate risk assessment (109). 
Regarding health and insurance behavior, participants learning that they had the APOE4 allele 
were more likely to change their long-term care insurance, compared to APOE4 negative 
patients. No differences were found on the basis of lifetime risk estimates. After one year, 53 % 
of APOE4 positive participants reported at least one positive health behavior change (e.g. 
exercise or diet), while the same was true for only 24 % of APOE4 negative participants and 31 
% of controls, indicating that AD risk information in the form of genetic susceptibility testing 
may motivate engagement in risk reduction activities (109). 
Results from the REVEAL study of 2005 suggest that most participants experienced the same or 
lower levels of anxiety about AD following risk disclosure, and there were no significant posttest 
group differences within the first year after information was given. In some sub-groups APOE4 
negative participants reported lower levels of anxiety. It is important to note that the study put a 
lot of emphasis on educating its participants on many aspects of the testing and the disease (109). 
The results of a second REVEAL study were published in 2009. No significant differences in 
levels of anxiety, depression or test-related distress were found in this study either, but the 
consensus remains that asymptomatic persons should not be tested for APOE genotype. In both 
studies people with high depression or anxiety scores were screened out before initiation of 
testing, and the emotional effect of risk disclosure is still a major concern. In the future, these 
concerns may be outweighed if APOE genotyping is discovered to predict for instance treatment 
efficacy or a risk of side effects (110). 
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In adapting treatment 
Current treatment of AD is based on the use of two classes of drugs. Cholinesterase inhibitors are 
designed to combat impairment of cholinergic neurons by slowing degradation of acetylcholine 
after its release at synapses. Memantine is meant to prevent overstimulation of a certain subtype 
of glutamate receptors, which are perceived to contribute to the pathogenesis of AD (111;112). 
In clinical trials, both cholinesterase inhibitors and memantine have shown beneficial but modest 
effects on cognitive scores and daily function (113;114), however, their cost effectiveness has 
been questioned (115). None of these drugs specifically target apoE in any way. 
Future therapeutic strategies for AD will most likely involve targeting the main culprits of the 
disease, such as Aβ and tau (116). Approaches to targeting these substances may involve 
interacting with the different isoforms of apoE (TABLE 2) (57). As apoE4 is a strong risk factor 
for AD, whereas apoE3 is not, one attractive approach is to convert apoE4 to an apoE3-like 
molecule. The domain interaction that exists in apoE4 but not in apoE3 seems to be responsible 
for most of the apoE4-associated neuropathology, and as such provides a possible target. A few 
molecules that can disrupt the apoE4 domain interaction have been identified in vitro, but 
whether they can diminish apoE4’s toxic functions in humans is currently unknown (117). 
 
 
  
Another potential strategy is to regulate apoE expression levels in the brain, perhaps by 
interacting with promoter polymorphisms of the APOE gene (118). However, this strategy 
requires careful consideration into whether apoE4 effects in the brain are caused by a loss of 
protection, a gain of toxicity, or both (57). It has been demonstrated that apoE4 has a faster 
turnover and lower steady-state concentration in APOE4 TR mice than in APOE3 TR mice, 
suggesting that low levels of APOE4 may directly contribute to AD pathogenesis, perhaps due to 
reduced apoE function in lipid metabolism, synaptic repair and Aβ clearance (119). Therefore, 
increasing the expression of apoE in all APOE genotypes may prevent or slow disease 
Table 2 | Strategies of APOE- and APOE receptor-based AD therapy (Bu 2009). 
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progression. However, increasing the expression of apoE4 in particular, may also generate 
deleterious effects such as slowing Aβ clearance through the BBB (76) and augmenting Aβ 
neurotoxicity (120).  
There are several other strategies that involve interacting with apoE (Table 1), but they do not 
differentiate between apoE isoforms. However, strategic combinations of modulations of the Aβ 
and apoE pathways, whether they pertain to apoE4 or not, remain highly promising avenues of 
investigation for combating AD (57). As none of these strategies are ready for clinical use, they 
do not affect the current consensus on predictive genetic testing (116). 
A 2009 review by Low et al. systematically reviewed the influence of apoE on the effects of 
potentially modifiable mid and late life risk factors for dementia, such as cardiovascular factors, 
lifestyle risk factors, medications, and other risk factors. The reviewers found only a few 
associations between apoE4, dementia and risk factors. That the detrimental effect of current 
smoking is limited only to persons without apoE4 was shown by four out of four available 
studies. Three out of four available studies showed that apoE4 increases the risk of dementia 
associated with greater fat consumption. Three out of five studies showed that apoE4 increases 
the protective effect against dementia associated with the use of hormone replacement therapy, 
while one out of the two non-significant studies suggested a trend. The review found evidence 
that apoE4 does not modify the risk of dementia associated with measures of, and treatments for 
cardiovascular disease, other dietary factors, or estradiol levels. For all other risk factors 
reviewed, there was inconsistent or contradictory evidence. Low et al. concluded that there is 
insufficient evidence for the recommendation of APOE genotyping to assist with tailoring risk 
reduction recommendations for dementia (121). 
 
Association with other diseases in the 21st century 
The APOE4 allele used to be considered a risk factor for an array of other diseases, including 
several neurodegenerative ones. Although initially associated with elevated cholesterol-levels 
and cardiovascular disease, more recent studies have shed some doubt on the assumption that the 
APOE4 allele in itself is a risk factor. A 2007 review concludes that the effect of APOE4 on 
cardiovascular disease is dependent on ethnicity, environmental background, and age (122). 
Recent studies have contradicted previous assumptions that APOE4 is associated with low bone 
mineral density and osteoporosis, this apparent contradiction may be due to the same set of 
circumstances as for cardiovascular disease (123-125). HIV-positive homozygous carriers of 
APOE4 have been shown to exhibit a more rapid disease progression, and especially a more 
rapid progression to death than homozygous carriers of APOE3. Interestingly, the same was not 
detected for the progression of HIV-associated dementia, a neurological condition with 
clinicopathological features similar to those of AD (126). No certain pathogenetically relevant 
mechanism has been observed linking APOE4 to multiple sclerosis (MS), and as of now we can 
  23 
 
only assume subtle effects of the apoE isoforms on the progression of MS (127). A 2008 review 
found that Parkinson’s disease dementia (PDD) is not related to APOE4, and concludes that 
there are different pathological mechanisms that lead to PDD and AD (128). The APOE4 allele 
has been reported to hasten the progression of diabetic neuropathy (129), but is not a 
susceptibility gene for idiopathic or diabetic neuropathy (130). Studies conducted on the 
association between the APOE4 allele and AD in persons with Down syndrome have yielded 
inconsistent results (131). 
The association between APOE4 and cerebral amyloid angiopathy, however, remains clear, as 
concluded in a 2009 review (132).  
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CONCLUSION 
 
It is clear that the APOE4 allele is a strong risk factor for LOAD, although the amount it risk it 
conveys is somewhat dependent on the ethnical and environmental backdrop. For Caucasians, 
APOE4 increases the risk greatly, in a dose-dependent fashion, putting homozygotes at an even 
greater risk than heterozygotes. An emerging body of data has identified multiple pathways that 
could explain the pathogenic nature of APOE4. These include Aβ production and clearance, 
neurotoxicity, tangle formation, cholesterol homeostasis, and neuronal plasticity and repair. 
From these, we must hope to identify the pathways most relevant to the pathogenesis of LOAD, 
and the ones that present opportunities for treating the disease more efficiently than today.  
As of today, testing for APOE genotype offers no obvious benefits to patient. It does not present 
us with any certainty of prognosis, there is no available treatment that differentiates between 
genotypes, and there is insufficient evidence that APOE testing will assist in risk reduction 
approaches. However, research does not show any significant detrimental effect on patients’ 
mental health from testing, and, hopefully, as new treatments and risk reduction schemes are 
developed, APOE genotyping will have its benefits soon enough.  
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